<DOC>
	<DOCNO>NCT02071459</DOCNO>
	<brief_summary>Evaluate effect L-Threo DOPS orthostatic hypotension symptom non-motor symptom patient Multiple System Atrophy ( MSA ) 12 week follow randomization continue therapy droxidopa placebo .</brief_summary>
	<brief_title>Efficacy L-threo DOPS Orthostatic Hypotension Symptoms Other Non-motor Symptoms Patients With MSA</brief_title>
	<detailed_description>Background : Multiple system atrophy ( MSA ) rare , sporadic progressive neurodegenerative disorder , rapidly lead severe disability impairment quality life . MSA characterize variable combination poor levodopa parkinsonism /or cerebellar ataxia autonomic failure ( cardiovascular / bladder sexual dysfunction ) ( Gilman et al , 2008 ) . The prevalence approximately 4-5 case per 100 000 inhabitant . Orthostatic hypotension ( OH ) one major symptom MSA , present large majority patient , lead significant disability impair balance , fall possibly syncope . Drugs available treat OH disease limit . L-ThreoDOPS ( L DOPS DroxiDopa ) orally administer synthetic catecholamine acid convert sympathetic neurotransmitter norepinephrine ( NE ) single step decarboxylation endogenous enzyme 3,4-dihydroxyphenylalanine ( DOPA ) decarboxylase . It prevent symptom related OH central and/peripheral mechanism . This drug currently develop `` neurogenic OH '' Chelsea Therapeutics basis short duration placebo-controlled randomized trial . Besides expect effect OH , L-DOPS may also , noradrenergic stimulation , improve motor non-motor symptom common disable MSA patient akinesia fatigue . In context , French reference center MSA 12 national center identify skill manage disease , propose conduct national multicenter randomize clinical trial versus placebo evaluate long term efficacy ( 3 month ) L-threo DOPS OH non-motor symptom MSA patient .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Hypotension</mesh_term>
	<mesh_term>Multiple System Atrophy</mesh_term>
	<mesh_term>Shy-Drager Syndrome</mesh_term>
	<mesh_term>Hypotension , Orthostatic</mesh_term>
	<mesh_term>Droxidopa</mesh_term>
	<criteria>MSA patient ( possible probable , MSAP C ( accord revise criterion , Gilman et al 2008 ) ) . Aged 30 80 year , Able walk least 10 meter With symptomatic OH ( score least 3 one item Part I OH scale ( OHQ ) ) Documented fall systolic blood pressure least 20 mmHg , and/or diastolic blood pressure least 10 mmHg , within 3 minute stand . Able fill evaluation questionnaire without help With significant problem swallow . Stable antiparkinsonian , dysautonomia depression treatment 4 week study entire study Signed write informed consent present study . Dementia ( DSMIV , MiniMental State Examination ( MMSE ) &lt; 24/30 ) Concomitant use vasoconstrictive drug , midodrine . Patients take vasoconstrictor agent ephedrine , dihydroergotamine , must stop take drug least 2 day 7 halflives prior baseline visit ( Visit 1 ) ; association midodrine may keep stable dose exceed 3 tablet ( 7.5 mg ) / day patient CV history . This discussed case case coordinate center safety committee study . Taking antihypertensive medication</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>L-threo DOPS ( DroxiDopa )</keyword>
	<keyword>Orthostatic Hypotension</keyword>
	<keyword>Multiple system atrophy</keyword>
</DOC>